Fulgent Genetics
FLGT
15 hedge funds and large institutions have $3.84M invested in Fulgent Genetics in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 4 closing their positions.
1.39% less ownership
Funds ownership: 8.09% → 6.7% (-1.4%)
12% less funds holding
Funds holding: 17 → 15 (-2)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
33% less capital invested
Capital invested by funds: $5.73M → $3.84M (-$1.9M)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$290K |
| 2 |
OWIM
Old West Investment Management
Los Angeles,
California
|
+$120K |
| 3 |
Brown Advisory
Baltimore,
Maryland
|
+$50.8K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.53K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$894K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$160K |
| 3 |
MA
Mutual Advisors
Omaha,
Nebraska
|
-$157K |
| 4 |
RA
Royce & Associates
New York
|
-$124K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$99K |
FLGT Hedge Fund Activity: Q4 2018 in Review
15 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Fulgent Genetics (FLGT) for Q4 2018, worth a combined $3.84M — down 33% from $5.73M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of FLGT and 3 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 2 added.
The largest buyer was Essex Investment Management, opening a new position worth an estimated $290K. The largest seller was Granahan Investment Management, exiting entirely with an estimated $894K sold.
- 15 institutional investors held Fulgent Genetics (FLGT) as of Q4 2018, down from 17 in Q3 2018.
- Funds reported $3.84M of Fulgent Genetics stock for Q4 2018, down 33% quarter-over-quarter.
- 3 funds opened new Fulgent Genetics positions in Q4 2018 and 4 closed out, a net change of -1 holder.
- The largest Fulgent Genetics buyer in Q4 2018 was Essex Investment Management, an estimated $290K added.
- The largest Fulgent Genetics seller in Q4 2018 was Granahan Investment Management, an estimated $894K sold.
Based on aggregated 13F filings for Q4 2018.